Table 2. Characteristics according to induction therapy.
| Total Study Population | Patients with Induction Tx. | ||||||
|---|---|---|---|---|---|---|---|
| Induction(-) | Induction(+) | p-value | Basiliximab | ATG | p-value | ||
| n = 15 | n = 621 | n = 542 | n = 79 | ||||
| Age | 42.8±13.0 | 45.4±12.6 | 0.191 | 45.1±12.9 | 47.6±10.7 | 0.061 | |
| Male, n (%) | 11 (73.3) | 366 (58.9) | 0.301 | 321 (59.2) | 45 (57.0) | 0.715 | |
| DDKT, n (%) | 0 (0.0) | 252 (40.6) | 0.001 | 206 (38.0) | 46 (58.2) | 0.001 | |
| Retransplant, n (%) | 0 (0.0) | 45 (7.2) | 0.616 | 30 (5.5) | 15 (19.0) | <0.001 | |
| Highly sensitized, n (%) | 1 (6.7) | 77 (12.4) | 0.708 | 53 (9.8) | 24 (30.4) | <0.001 | |
| ABO incompatibility, n (%) | 2 (13.3) | 83 (13.5) | 1.000 | 66 (12.3) | 17 (21.5) | 0.033 | |
| ISx Change, n (%) | 1 (6.7) | 250 (40.3) | 0.007 | 204 (37.6) | 46 (58.2) | 0.001 | |
| Graft Failure, n (%) | 0 (0.0) | 2 (0.3) | 1.000 | 2 (0.4) | 0 (0.0) | 1.000 | |
| eGFR (mL/min/1.73m2) | |||||||
| At KT | 74.7±20.1 | 72.2±25.1 | 0.704 | 72.6±24.7 | 69.1±27.4 | 0.250 | |
| 1-year after KT | 65.7±13.2 | 63.9±21.1 | 0.748 | 64.4±21.1 | 60.4±21.0 | 0.115 | |
| ∆eGFR (1 year) | -7.1 (28.2) | -8.0 (23.2) | 0.960 | -7.6 (23.1) | -10.2 (26.3) | 0.641 | |
Continuous variables with normal distributions are presented with mean±S.D.
Continuous variables without normal distributions are presented with median (interquartile range).
∆eGFR represented the slope of eGFR between the time of discharge and 1-year after the transplantation.
Abbreviation: Tx., treatment; ATG, anti-thymocyte globulin; DDKT, deceased-donor kidney transplantation; ISx, immunosuppressant; eGFR, estimated glomerular filtration rate.